PMID- 21663512
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 52
IP  - 10
DP  - 2011 Oct
TI  - The prognostic relevance of tumor associated macrophages in advanced stage 
      classical Hodgkin lymphoma.
PG  - 1913-9
LID - 10.3109/10428194.2011.580026 [doi]
AB  - Although the treatment of Hodgkin lymphoma (HL) has been improved, distinguishing 
      reliable prognostic biomarkers could better stratify patients for more effective 
      treatment. We analyzed the prognostic relevance of CD68+ tumor-associated 
      macrophages (TAMs) by immunohistochemical analysis at diagnosis and standard 
      clinical parameters in 52 ABVD (doxorubicin, bleomycin, vinblastine, 
      dacarbazine)-treated patients with advanced stage classical HL (cHL). Patients 
      with >25% CD68+ TAMs compared to those with </=25% had worse 5-year overall 
      survival (45% vs. 77%, log-rank p = 0.019) and showed a trend toward shorter 
      5-year event-free survival (51% vs. 71%, log-rank p = 0.19). Additionally, no 
      significant correlation with selected clinical features was found. Significantly 
      shorter 5-year overall survival was associated with International Prognostic 
      Score (IPS) >2, bulky disease, elevated erythrocyte sedimentation rate (log-rank 
      test, p = 0.003, p = 0.049, p = 0.007, respectively). In multivariate analysis, 
      increased CD68+TAMs, IPS >2, and bulky disease were identified as independent 
      prognostic factors for overall survival (Cox multivariate model, p = 0.006, 
      p = 0.007, p = 0.013, respectively). Tumor-associated macrophages represent a 
      potential prognostic biomarker which could contribute to better risk 
      stratification of patients with cHL.
FAU - Jakovic, Ljubomir R
AU  - Jakovic LR
AD  - Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia. 
      ljubajak@yahoo.com
FAU - Mihaljevic, Biljana S
AU  - Mihaljevic BS
FAU - Perunicic Jovanovic, Maja D
AU  - Perunicic Jovanovic MD
FAU - Bogdanovic, Andrija D
AU  - Bogdanovic AD
FAU - Andjelic, Bosko M
AU  - Andjelic BM
FAU - Bumbasirevic, Vladimir Z
AU  - Bumbasirevic VZ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110612
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD68 antigen, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, CD/*analysis
MH  - Antigens, Differentiation, Myelomonocytic/*analysis
MH  - Biomarkers, Tumor/analysis
MH  - Female
MH  - Hodgkin Disease/immunology/mortality/*pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - *Macrophages/immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Young Adult
EDAT- 2011/06/15 06:00
MHDA- 2012/03/23 06:00
CRDT- 2011/06/14 06:00
PHST- 2011/06/14 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
AID - 10.3109/10428194.2011.580026 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2011 Oct;52(10):1913-9. doi: 10.3109/10428194.2011.580026. Epub 
      2011 Jun 12.